Antonio Passaro

9.0k total citations · 5 hit papers
120 papers, 3.4k citations indexed

About

Antonio Passaro is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Antonio Passaro has authored 120 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Pulmonary and Respiratory Medicine, 85 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Antonio Passaro's work include Lung Cancer Treatments and Mutations (101 papers), Lung Cancer Diagnosis and Treatment (33 papers) and Lung Cancer Research Studies (33 papers). Antonio Passaro is often cited by papers focused on Lung Cancer Treatments and Mutations (101 papers), Lung Cancer Diagnosis and Treatment (33 papers) and Lung Cancer Research Studies (33 papers). Antonio Passaro collaborates with scholars based in Italy, United States and United Kingdom. Antonio Passaro's co-authors include Solange Peters, Tony Mok, Filippo de Marinis, Pasi A. Jänne, Ilaria Attili, David Planchard, Jessica Menis, Gianluca Spitaleri, Egbert F. Smit and Keith M. Kerr and has published in prestigious journals such as Cell, Journal of Clinical Oncology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Antonio Passaro

111 papers receiving 3.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 370 citations Antonio Passaro, David Planchard et al. Annals of Oncology profile →
Overcoming therapy resistance in EGFR-mutant lung cancer

2021 338 citations Antonio Passaro et al. profile →
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 286 citations Antonio Passaro, David Planchard et al. Annals of Oncology profile →
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

2024 235 citations Antonio Passaro et al. profile →
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies

2022 178 citations Antonio Passaro et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio Passaro Italy	28	2.2k	2.1k	1.0k	741	265	120	3.4k
Jordi Remón France	34	2.4k 1.1×	2.1k 1.0×	1.0k 1.0×	977 1.3×	261 1.0×	175	3.7k
Christina S. Baik United States	27	1.8k 0.8×	2.1k 1.0×	1.3k 1.3×	685 0.9×	339 1.3×	116	3.5k
Alessandro Russo Italy	31	1.4k 0.6×	1.5k 0.7×	872 0.9×	840 1.1×	158 0.6×	125	2.7k
Anne C. Chiang United States	19	1.2k 0.6×	1.9k 0.9×	1.1k 1.1×	682 0.9×	225 0.8×	88	3.1k
Daniel S.W. Tan Singapore	34	1.9k 0.9×	1.8k 0.9×	1.3k 1.3×	965 1.3×	321 1.2×	159	4.1k
Dean A. Fennell United Kingdom	32	2.4k 1.1×	1.6k 0.8×	1.5k 1.5×	562 0.8×	288 1.1×	114	4.5k
Marzia Del Re Italy	34	1.6k 0.7×	1.6k 0.8×	1.5k 1.5×	1.3k 1.7×	250 0.9×	167	3.9k
Kun He United States	27	1.3k 0.6×	2.0k 1.0×	835 0.8×	475 0.6×	578 2.2×	53	3.2k
Alex Y. Chang Singapore	21	2.7k 1.2×	2.5k 1.2×	1.1k 1.1×	737 1.0×	112 0.4×	39	4.1k
Paolo Maione Italy	31	2.0k 0.9×	2.2k 1.1×	1.1k 1.1×	452 0.6×	169 0.6×	138	3.6k

Countries citing papers authored by Antonio Passaro

Since Specialization

Citations

This map shows the geographic impact of Antonio Passaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Passaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Passaro more than expected).

Fields of papers citing papers by Antonio Passaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Passaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Passaro. The network helps show where Antonio Passaro may publish in the future.

Co-authorship network of co-authors of Antonio Passaro

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Passaro. A scholar is included among the top collaborators of Antonio Passaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Passaro. Antonio Passaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Angelopoulos, Panagiotis, Antonio Passaro, Ilaria Attili, et al.. (2025). Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer. Genes. 16(7). 772–772. 1 indexed citations

Attili, Ilaria, Luca Bertolaccini, Carla Corvaja, et al.. (2025). Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study. Clinical Lung Cancer. 27(2). 259–268.e8.

Califano, Raffaele, SH Lee, Yuzhuo Wang, et al.. (2024). LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2. Annals of Oncology. 35. S1244–S1245. 6 indexed citations

Spira, Alexander I., Byoung Chul Cho, Enriqueta Felip, et al.. (2024). PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004). Journal of Thoracic Oncology. 19(7). e17–e18.

Leighl, Natasha B., Hiroaki Akamatsu, Ying Cheng, et al.. (2024). Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA8505–LBA8505. 12 indexed citations

Spira, Alexander I., Byoung Chul Cho, Enriqueta Felip, et al.. (2024). FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Lung Cancer. 199. 108066–108066. 2 indexed citations

Aliaga, Pamela Trillo, Ester Del Signore, Gianluca Spitaleri, et al.. (2024). The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics. Genes. 15(6). 701–701. 1 indexed citations

Attili, Ilaria, Gianluca Spitaleri, Carla Corvaja, et al.. (2024). Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials. Cancers. 16(13). 2457–2457. 4 indexed citations

Spitaleri, Gianluca, Pamela Trillo Aliaga, Ilaria Attili, et al.. (2024). Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”. Cancers. 16(16). 2877–2877. 2 indexed citations

10.

Attili, Ilaria, Davide Vacirca, Alessandra Rappa, et al.. (2024). Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis. Journal of Clinical Medicine. 13(15). 4476–4476. 5 indexed citations

11.

Attili, Ilaria, Carla Corvaja, Gianluca Spitaleri, et al.. (2024). Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings. Cancers. 16(14). 2589–2589. 7 indexed citations

12.

Attili, Ilaria, Carla Corvaja, Pamela Trillo Aliaga, et al.. (2024). Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario. Current Oncology. 31(9). 5121–5139. 7 indexed citations

13.

Passaro, Antonio, Byoung Chul Cho, Yan Wang, et al.. (2023). LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. Annals of Oncology. 34. S1307–S1307. 8 indexed citations

14.

Spitaleri, Gianluca, Pamela Trillo Aliaga, Ilaria Attili, et al.. (2023). MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target. Cancers. 15(19). 4779–4779. 12 indexed citations

15.

Cucchiara, Federico, Iacopo Petrini, Antonio Passaro, et al.. (2022). Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival. Clinical Lung Cancer. 23(6). 510–521. 3 indexed citations

16.

Passaro, Antonio, Silvia Novello, Diana Giannarelli, et al.. (2021). Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers. 13(12). 2935–2935. 14 indexed citations

17.

Malapelle, Umberto, Sara Pilotto, Maria Lucia Reale, et al.. (2021). Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. Critical Reviews in Oncology/Hematology. 169. 103536–103536. 11 indexed citations

18.

Re, Marzia Del, Stefania Crucitta, Antonio Passaro, et al.. (2019). Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. International Journal of Molecular Sciences. 20(16). 3951–3951. 62 indexed citations

19.

Passaro, Antonio, et al.. (2016). Nivolumab nel trattamento della seconda linea del tumore polmonare non a piccole cellule a istologia squamosa. Recenti Progressi in Medicina. 107(12). 634–640. 1 indexed citations

20.

Catania, Chiara, Edoardo Botteri, Massimo Barberis, et al.. (2015). Molecular Features and Clinical Outcome of Lung Malignancies in Very Young People. Future Oncology. 11(8). 1211–1221. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact